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Abstract 
Background: Previous trials on the effectiveness of genotype-guided warfarin dosing versus 
conventional dosing have been inconclusive. We conducted a systematic review and meta-
analysis of randomized trials comparing genotype-guided to conventional dosing strategies. 
Methods: PubMed and Cochrane Library were searched until 23
rd
 October 2017.  
Results: A total of 76 and 94 entries were retrieved. A total of 2626 subjects in the genotype-
guided dosing (mean age:  63.3 ± 5.8 years; 46% male) and 2604 subjects in the conventional 
dosing (mean age: 64.7 ± 6.1 years; 46% male) groups (mean follow-up duration: 64 days) 
from 18 trials were included. Compared to conventional dosing, genotype-guided dosing 
significantly shortened the time-to-first therapeutic INR (mean difference: 2.6 days, standard 
error: 0.3 days, P<0.0001; I
2
: 0%) and time-to-first stable INR (mean difference: 5.9 days, 
standard error: 2.0 days, P<0.01; I
2
: 94%). Genotype-guided dosing also increased the Time 
in Therapeutic Range (TTR) (mean difference: 3.1%, standard error: 1.2%, P<0.01; I
2
: 80%), 
and reduced the risks of both excessive anticoagulation defined as INR ≥ 4 (risk ratio [RR]: 
0.87; 95% CI: 0.78-0.98; P<0.05; I
2
: 0%) and bleeding (RR: 0.82; 95% CI: 0.69-0.98; P<0.05; 
I
2
: 31%). No difference in thromboembolism (RR:  0.84; 95% CI: 0.56-1.26; P=0.40; I
2
: 0%) 
or mortality (RR: 1.16; 95% CI: 0.46-2.91; P=0.76; I
2
: 0%) was observed between the two 
groups. 
Conclusions: Genotype-guided warfarin dosing offers better safety with less bleeding 
compared to conventional dosing strategies. No significant benefit on thromboembolism or 
mortality was evident. 
Key words: warfarin; dosing; genotype; CYP2C9; VKORC1; CYP4F2 
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Introduction 
Warfarin is one of the commonest prescribed drug, accounting for more than 35 
million prescriptions in the United States alone (1). However, it is also responsible for more 
iatrogenic accident and emergency department visits in elder patients compared to other 
medications (2, 3). This may be related to over- or under-dosing because of wide inter-
individual variability in dosing requirements. To better optimize anticoagulation control, the 
use of genetic-based algorithms, collectively termed genotype-guided dosing, has been 
devised. However, previously published randomized controlled trials (RCTs) comparing the 
effects of genotype-guided dosing against conventional dosing (either fixed dosing or 
clinically-guided dosing) strategies (4-14), and even their subsequent meta-analyses have 
yielded conflicting results (15-21). A meta-analysis published in 2015, which pooled the 
evidence from 11 RCTs with trial sequential analysis (21), reported shorter time taken to 
reach first therapeutic or stable International Normalised Ratio (INR), improvements in 
markers of anticoagulation control such as the time in therapeutic range (TTR) and the 
number of patients with out-of-range INR, but this did not translate into better clinical 
outcomes of reducing bleeding, thromboembolism or mortality.  
Since the publication of this study, six additional trials have been published on this 
issue (22-27), with the most recent three showing conflicting results. For example, a RCT 
conducted in 2015 on non-valvular atrial fibrillation patients reported no significant 
difference in TTR or in the number of patients with out-of-range INR (22). Similarly, in a 
group of Han Chinese, TTR, excessive anticoagulation or adverse events did not differ 
between the genotype-guided and optimal clinical care arms (27). By contrast, the recently 
published Genetic Informatics Trial (GIFT) of Warfarin to Prevent Deep Vein Thrombosis in 
patients receiving warfarin at the time of elective hip or knee arthroplasty reported significant 
benefits with genotype-guided dosing when compared to clinically-guided dosing (25). In 
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GIFT, genotype-guided warfarin dosing increased the TTR, and reduced the combined risk of 
major bleeding, INR of 4 or greater, venous thromboembolism, or death. Given these new 
findings, we conducted a systematic review and meta-analysis of all randomized trials to 
evaluate the benefits and complication rates in genotype-guided dosing versus conventional 
dosing strategies. 
 
Methods 
Search strategy, inclusion and exclusion criteria 
The systematic review and meta-analysis was performed according to the PRISMA 
statement (28). PubMed and Cochrane Library were searched for randomized trials that 
compared the efficacy in genotype-guided warfarin dosing compared to conventional dosing 
strategies. The following search terms were used for PubMed: [genotype AND warfarin AND 
randomized trial]. For Cochrane Library, the following terms were used: ["genotype " AND 
"warfarin"]. The search period was from 1966 for Pubmed and 1996f for Cochrane Library 
through to 23
rd
 October 2017, with no language restrictions. The following inclusion criteria 
were applied: i) the design was a randomized trial in humans, ii) the study compared 
outcomes for genotype-guided versus conventional warfarin dosing strategies. Reference lists 
of included studies, and of previous meta-analyses identified, were searched. No additional 
studies were found. Given the recently published PRISMA-compliant systematic review and 
meta-analysis studies, a more robust search strategy used. Previously, the Tang 2015 meta-
analysis was performed using the [(genotype OR polymorphism OR gene OR allele OR 
variant OR mutation OR single-nucleotide polymorphism) AND (algorithms OR regimen OR 
model OR strategy)] AND (warfarin OR coumarin OR anticoagula*). The same terms were 
searched in PubMed between 1
st
 February 2017 and 31
st
 March 2018, yielding an additional 
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128 studies. This failed to identify any further relevant studies (Supplementary Figure 1). 
Quality assessment of randomized controlled trials was performed using the Cochrane Risk 
Assessment Tool (Supplementary Figures 2 and 3).  
 
Data extraction  
Data from the different studies were entered in Microsoft Excel. All publications 
extracted from the search strategy were assessed for compliance with the inclusion criteria. In 
this meta-analysis, the extracted data elements consisted of: i) last name of first author and 
year of publication; ii) target INR, iii) follow-up duration; iv) characteristics of the genotype-
guided and control groups including sample size, sex and age, v) genes tested and dosing 
algorithm for the genotype-guided group, vi) dosing algorithm and whether fixed dose or 
clinical information-guided was used for the control group. The search of the two databases 
was conducted by GT. The search results were then retrieved and independently screened by 
GT and MG. Any disagreements would be brought to the attention of a third reviewer (TL). 
However, this was not required as both reviewers arrived at the same list of RCTs for 
inclusion in the meta-analysis.   
Endpoints and statistical analysis 
The a priori pre-defined endpoints for this meta-analysis were: 1) time-to-first 
therapeutic INR, 2) time-to-first stable INR, 3) time in therapeutic range (TTR), number of 
patients with 4) excessive anticoagulation defined as INR ≥  4, 5) bleeding, 6) 
thromboembolism and 7) mortality. For time-to-first therapeutic INR, time-to-first stable INR 
and TTR, mean difference between the genotype-guided dosing and conventional dosing 
strategies was extracted or calculated. For INR ≥  4, bleeding, thromboembolism and 
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mortality, risk ratios were calculated. Where the data concerning a particular endpoint were 
not available, they were obtained from previously published meta-analyses. 
Heterogeneity across studies was assessed using the I
2
 statistic from the standard chi-
square test, which describes the percentage of the variability in the effect estimates resulting 
from heterogeneity. I
2
 > 50% was considered to reflect significant statistical heterogeneity 
and in such cases the random-effects model using the inverse-variance approach was used. 
Otherwise, the fixed-effects model was used. To explore the potential sources of the 
heterogeneity, subgroup analysis based on the type of warfarin dosing for the control group 
(fixed dose and clinical information-guided) was performed. Funnel plots showing standard 
errors against the mean difference or against the logarithms of the risk ratios were constructed. 
The Egger’s test was used to detect publication bias. 
 
Results 
A QUORUM diagram detailing the above search terms with inclusion and exclusion 
criteria is depicted in Figure 1. A total of 76 and 94 studies were retrieved from PubMed and 
Cochrane Library, respectively. However, 152 studies did not meet the inclusion criteria. 
Therefore, a total of 18 trials were included in this meta-analysis (4-14, 22-27, 29). The 
baseline characteristics of these studies are listed in Table 1. This meta-analysis included 
2626 patients in the genotype-guided dosing arm (mean age: 63.3 ± 5.8 years; 46% male) and 
2604 patients in the conventional dosing arm (mean age: 64.7 ± 6.1 years; 46% male). The 
mean follow-up duration was 64 days. For the control group, two conventional dosing 
strategies have been used. The first is fixed dosing, where the patients received a fixed dose 
for a fixed number of days. This varied from 2.5 mg to 6 mg for 3-7 days, 10 mg-5 mg-5 mg 
regimens were also used. The lower doses were used in Chinese populations where warfarin 
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requirements are lower. For clinical information-guided dosing, the different definitions are 
illustrated in Table 1. This involved the use of regression models based on different clinical 
parameters such as age, gender, body surface area and valve status. For the genotype-guided 
group, 12 different algorithms were described in the 18 trials, incorporating the 
polymorphisms for CYP2C9, VKORC1, CYP4F2 to determine the warfarin dose 
(Supplementary Table 1). 
Quality assessment of randomized controlled trials was performed using the Cochrane 
Risk Assessment Tool (Supplementary Figures 2 and 3). Overall, risk of bias assessment 
could be conducted for 16 of the 18 trials conducted, whereas the remaining two studies were 
conference abstracts (24, 29), which could not be judged on their quality due to the lack of 
information reported. One study (6) was deemed to be of low quality and whereas the 
remaining 15 studies generally showed high quality study designs for reducing risk of bias. 
Specifically, for random sequence generation, nine of the 18 trials included a low risk of bias. 
Similarly, for allocation concealment, only eight trials had an appropriate design to reduce 
selection bias. Nevertheless, to reduce performance bias, 12 trials had described proper 
blinding of participants and research personnel. For blinding of outcome assessment, most 
studies did not clearly illustrate an appropriate method except for two trials, which had low 
risk of attrition bias. On selective reporting, 15 of the 18 trials had appropriately described 
their data on their different endpoints, which therefore had a low risk of reporting bias. 
Funnel plots showing standard errors against the mean difference or against the logarithms of 
the risk ratios are shown in Supplementary Figures 4 and 10.  
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Genotype-guided warfarin dosing leads to shorter time to first therapeutic INR and time to 
stable INR 
Seven studies provided information on the time taken to reach the first therapeutic 
INR (6, 9, 23, 25-27, 29), but only three of these provided sufficient information for the 
calculation of mean difference values (6, 9, 26) (Figure 2, top left panel). It was defined by 
Borgman 2012 study as “the time interval in days from the first warfarin dosage to the first 
time interval where the INR remains within the predefined acceptable range (INR 1.8 to 3.2) 
for a minimum of 4 consecutive days”. By contrast, the Coraco 2008 study, defined stable 
anticoagulation as “two consecutive INR values, 7 days apart, were within the therapeutic 
range, without any intervening dose alteration”. The Jin 2017 study defined it “as INR values 
maintained in the range of 2-3 for at least 3 times (≥ 7 days) continuously”. Our meta-
analysis shows a significant shorter time to reach the first therapeutic INR in the genotype-
guided dosing group when compared to controls, all of which used fixed dosing (mean 
difference: 2.6 days, standard error: 0.3 days, P < 0.0001; I
2
: 0%; Figure 2, top left panel). 
Egger’s test demonstrated no significant asymmetry (intercept 0.9, t-value 1.9; P > 0.05; 
Supplementary Figure 4). Subgroup analysis based on ethnicity showed that the mean 
differences remained statistically significant for each ethnicity (Figure 2, top right panel). 
For the time taken to reach a stable INR, four studies provided the median (8, 10, 14, 
23), and six studies reported the mean (6, 10, 11, 22, 26, 27). Of the latter six studies, one 
was excluded because standard deviation or another measure of dispersion was not available 
(27) (Figure 2, bottom left panel). Our meta-analysis of these five studies showed a shorter 
time to reach a stable INR with the genotype-guided dosing group (mean difference: 5.9 days, 
standard error: 2.0 days, P < 0.01; I
2
: 94%). Egger’s test demonstrated no significant 
asymmetry (intercept 0.6, t-value 0.2; P > 0.05; Supplementary Figure 5). Of the five 
studies, four used a fixed dosing regimen for the control group and the mean difference 
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remained statistically significant on subgroup analysis (Figure 2, bottom left panel). 
Subgroup analysis for ethnicity showed that the mean difference remained significant for 
Caucasians and Chinese subjects, but not in the study with both Caucasians and African 
subjects (Figure 2, bottom right panel). 
 
Genotype-guided warfarin dosing leads to higher time in therapeutic range and lower 
number of patients with excessive anticoagulation when compared to conventional dosing 
strategies 
Fourteen of the 18 trials reported TTR values (4-9, 11, 12, 14, 22, 23, 25, 27) but one 
study was excluded as no standard error, standard deviation or confidence interval was 
reported (24). Of the thirteen studies, five reported significantly higher TTRs in genotype-
guided therapy compared to conventional dosing strategies, whereas the remaining studies 
reported no difference in the two groups (Figure 3, top left panel). Nevertheless, our meta-
analysis shows that genotype-guided warfarin dosing significantly increased TTR compared 
to conventional dosing strategies (mean difference: 3.1%, standard error: 1.2%, P < 0.05; I
2
: 
80%). Egger’s test demonstrated no significant asymmetry (intercept 0.2, t-value 0.2; P > 
0.05; Supplementary Figure 6). Subgroup analysis showed that genotype-guided dosing 
produced greater TTR than fixed-dose regimens (mean difference: 7.4%, standard error: 2.0%, 
P < 0.0001; I
2
: 71%) (Figure 3, top left panel). By contrast, no significant difference in TTRs 
was observed between genotype-guided dosing and clinical information-guided regimens 
(mean difference: 0.5%, standard error: 1.5%, P = 0.73; I
2
: 55%). Subgroup analysis based on 
ethnicity showed that TTRs remained significantly different between both groups for 
Caucasians, Caucasians and Africans, and Chinese, with I
2
 taking values of 84%, 54%, 0%, 
respectively (Figure 3, top right panel). 
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Moreover, 13 of the 18 trials (4-9, 11, 12, 14, 22, 24, 25, 27) reported the number of 
individuals with excessive anticoagulation defined as INR ≥ 4 and the total of individuals in 
each group. Of these, two reported a reduction in the risk ratio for excessive anticoagulation 
in genotype-guided therapy compared to conventional dosing strategies, whereas eleven 
studies reporting no significant difference (Figure 3, bottom left panel). Our overall meta-
analysis demonstrated that genotype-guided warfarin dosing was associated with a lower risk 
of excessive anticoagulation (risk ratio [RR]: 0.87; 95% CI: 0.78-0.98; P < 0.05; I
2
: 0%). 
Egger’s test demonstrated no significant asymmetry (intercept 0.3, t-value 0.6; P > 0.05; 
Supplementary Figure 7). Subgroup analysis remained statistically significant when 
comparison was made to fixed-dose regimen (RR: 0.82; 95% CI: 0.68-0.99; P < 0.05; I
2
: 0%) 
but not to clinical information-guided regimen (RR: 0.91; 95% CI: 0.78-1.06; P = 0.22; I
2
: 
0%) (Figure 3, bottom left panel). Subgroup analyses based on ethnicity resulted in RRs that 
were no longer statistically significant for Caucasians, Caucasians with Africans and Chinese 
(Figure 3, bottom right panel). 
 
Genotype-guided warfarin dosing reduces bleeding without affecting thromboembolism or 
mortality compared to conventional dosing strategies 
Fourteen of the 18 trials reported bleeding events (4, 6-8, 11, 12, 14, 23-27, 29), but 
one was excluded from the analysis due to zero events in both groups (22). Two trials 
reported significantly reduction in bleeding using genotype-guided dosing, whereas the other 
trials did not report significant differences (Figure 4, top left panel). Our overall meta-
analysis shows that genotype-guided dosing was associated with a lower risk of bleeding (RR: 
0.82; 95% CI: 0.69-0.98; P < 0.05; I
2
: 31%). Egger’s test demonstrated significant asymmetry 
(intercept -1.4, t-value 4.1; P < 0.05; Supplementary Figure 8). Subgroup analyses based on 
control group dosing regimen led to loss of statistical significance for the RRs (fixed-dose 
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regimen: 0.86, 95% CI: 0.70-1.06; P = 0.16; I
2
: 22%; clinical information-guided regimen: 
0.76; 95% CI: 0.57-1.01; P = 0.06; I
2
: 45%) (Figure 4, top left panel). Subgroup analyses 
based on ethnicity showed that the risk of bleeding remained significantly lower for Chinese 
(RR: 0.46, 95% CI: 0.23-0.92; P < 0.05; I
2
: 0%), but not for Caucasians alone or Caucasians 
with Africans (Figure 4, top right panel). 
Thromboembolism was assessed by ten trials (4, 6, 8, 11, 12, 14, 22, 24, 25, 27), but 
three trials were excluded because zero events were reported for both genotype-guided dosing 
and conventional dosing groups. None of the remaining studies reported significant 
difference in thromboembolism events (Figure 4, bottom left panel), which is confirmed by 
our meta-analysis (RR: 0.84; 95% CI: 0.56-1.26; P = 0.40; I
2
: 0%). Egger’s test demonstrated 
no significant asymmetry (intercept -0.4, t-value 0.9; P > 0.05; Supplementary Figure 9). 
Subgroup analyses comparing against fixed-dose regimen (RR: 0.27; 95% CI: 0.03-2.38; P = 
0.24; I
2
: 0%) or clinical information-guided regimen (RR: 0.87; 95% CI: 0.58-1.32; P = 0.53; 
I
2
: 0%) did not significantly alter the findings (Figure 4, bottom left panel). Subgroup 
analyses based on ethnicity also did not alter our results (Figure 4, bottom right panel). It 
was possible to calculate the number of patients needed to be genotyped in order to reduce 
one adverse event based on the absolute risk difference. This was estimated to be 40 patients 
for major bleeding but 238 for thromboembolism.  
Mortality was reported in seven trials (8, 11, 12, 14, 23-25), but one was excluded 
from further analysis because of zero events in both groups (25). Of the remaining studies, 
none reported significant difference in mortality between both genotype-guided dosing and 
conventional dosing groups (Figure 5, left panel), which was confirmed by our meta-analysis 
(RR: 1.16; 95% CI: 0.46-2.90; P = 0.76; I
2
: 0%). Egger’s test demonstrated no significant 
asymmetry (intercept -1.1, t-value 0.8; P > 0.05; Supplementary Figure 10). Subgroup 
analyses comparing against fixed-dose regimen (RR: 2.63; 95% CI: 0.62-11.23; P = 0.19; I
2
: 
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0%) or clinical information-guided regimen (RR: 0.66; 95% CI: 0.20-2.19; P = 0.50; I
2
: 0%) 
did not significantly alter the findings. Similarly, subgroup analyses based on ethnicity did 
not alter the findings (Figure 5, right panel). 
Meta-regression analysis was conducted to explore potential influences of continuous 
moderator variables. Thus, meta-regression of TTR mean difference on the logarithm of risk 
ratios for INR ≥ 4 (Supplementary Figure 11), bleeding (Supplementary Figure 12), 
thromboembolism (Supplementary Figure 13) or mortality (Supplementary Figure 14) did 
not reveal slopes or intercepts that were significantly different from zero (P > 0.05). 
 
Discussion 
 The main findings of this meta-analysis are that, compared to conventional dosing 
strategies, genotype-guided warfarin dosing significantly 1) shortened the time to first 
therapeutic INR by 2.6 days, 2) shortened the time to first stable INR by 5.9 days, 3) 
improved TTRs by 3.1%, 4) reduced the number of patients with excessive anticoagulation 
(INR > 4) with an RR of 0.87, 5) reduced bleeding events with an RR of 0.82. No significant 
difference in the risk of 6) thromboembolism or 7) mortality was observed when comparing 
the two groups. 
Warfarin has been one of the commonest prescribed anticoagulant medications since 
its approval in 1954, although non-vitamin K oral anticoagulants may have been overtaken 
since 2012 (30). Inactivation of warfarin occurs when it is metabolized to the 7-hydroxy 
metabolite by CYP2C9 (31). Polymorphisms in CYP2C9 are known to reduce the activity of 
the enzyme, thereby less effective warfarin inactivation (32). Moreover, polymorphisms in 
both the VKORC1 and CYP2C9 genes contribute to the inter-individual variability in dosing 
requirements (33) and patients’ response to warfarin (34). Therefore, there has been 
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significant interests in whether genotype-guided dosing therapy will improve INR control and 
clinical outcomes for patients on warfarin. 
Previous randomized controlled trials comparing the effectiveness of genotype-guided 
dosing and conventional dosing strategies, and even meta-analyses of these trials, have been 
inconclusive (15-18). Nevertheless, a subsequent meta-analysis of 11 RCTs with trial 
sequential analysis has demonstrated improvements in biochemical parameters of INR 
control and TTRs, but limited clinical utility with genotype-guided dosing (21). However, 
since its publication, an additional seven trials have been published. Of these newer trials, the 
Genetic Informatics Trial (GIFT) of Warfarin to Prevent Deep Vein Thrombosis was the 
largest trial to date with the largest number of 1597 subjects. This trial contributed 
approximately one third of included cohort, reporting that genotype-guided dosing prevented 
more adverse outcomes than clinically-guided dosing in patients undergoing hip and knee 
surgery. In orthopedic surgery, surgeons often have more time to obtain genotype data and 
use this information to plan for the surgery. By contrast, physicians who encounter patients 
with atrial fibrillation or venous thromboembolism often have little time to obtain genotype 
data before prescribing anticoagulants.  
In our updated meta-analysis, our significant findings are that both biochemical 
measures of warfarin therapy were improved and bleeding complications were reduced. The 
endpoints were chosen as these were parameters that were critical for guiding the decision-
making process in clinical practice. For example, both time-to-first therapeutic INR and time-
to-stable INR can guide clinicians for deciding an appropriate follow-up duration and 
frequency. By contrast, TTR, INR ≥ 4 and risks of complications are important for resource 
allocation at the population level. The effect of genotype-guided warfarin dosing compared 
with conventional dosing on TTR is convincing and is clinically important. The significant 
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difference in TTR when a clinical information-guided warfarin dosing regimen is used in the 
conventional arm is striking.  
Two of the studies included in the meta-analysis only genotyped for CYP2C9 variants 
(4, 6). The COAG trial also determined the CYP2C9*2 and *3 only, but not for other 
CYP2C9 variants (12). This is important because other CYP2C9 variants are more frequently 
found than CYP2C9*2 and *3 in African Americans, who constituted nearly one third of the 
study population. Therefore, the advantages of genotype-guided warfarin dosing could be 
diminished in populations with African ancestry. Nevertheless, in the COAG trial, TTR was 
improved, excessive anticoagulation was reduced, and the number of adverse events were 
significantly reduced. Consequently, in our meta-analysis this had little impact on the overall 
pooled effect estimates for these endpoints. 
There are several considerations on the practicality of utilizing genotype-guided 
warfarin dosing. All of the included studies had applied complex proprietary algorithms for 
genotype testing to determine the suitable warfarin dose. Currently, it is unclear which 
algorithm is the best because no direct comparisons have been made. Currently, at least for 
physicians it is difficult to take the time for genotype-guided dosing to guide warfarin 
treatment during their busy workday, especially when a patient presents with acute venous 
thromboembolism or atrial fibrillation, anticoagulation needs to be started immediately. It 
may not be the case for orthopedic surgery, for which more time is available for planning of 
surgery and anticoagulation. It may well be that there are adequate time and resources for 
acquiring the genotype of patients in clinical trials or in university hospitals. The situation is 
different for doctors who are working in the average clinic or hospital without significant 
resources that can be used for such testing. Nevertheless, a feasibility study examined the 
procedural feasibility of a pharmacist-led interdisciplinary service for providing genotype-
guided warfarin dosing for hospitalized patients newly starting warfarin (35). When these 
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tools were embedded into electronic health records, the majority of genotypes were available 
before the second warfarin dose and good adherence to genotype-guided dose 
recommendations by the medical staff was observed.  
We estimated that genotyping is needed for 40 individuals to reduce one major 
bleeding event. By contrast, it is needed for 238 individuals to reduce one thromboembolic 
event. These findings suggest that genotype-guided warfarin dosing could be worthwhile for 
individuals who are at high risk of bleeding. A related key issue is whether the benefits of 
genotype-guided dosing are cost-effective. The widespread and increasing use of non-VKA 
anticoagulants is likely to strongly diminish the impact of genotype-driven dosing for VKA. 
For patients who are prescribed warfarin, the cost of genotyping is relatively modest and 
likely to be much less costly than the costs for hospital admissions, length of stay and 
medical or interventional treatment due to bleeding. Since cost effectiveness may also vary 
with the baseline risk of bleeding of the patients concerned, depending on the comorbidities, 
this issue requires formal health economic analyses in future studies to determine the subset 
of patients on warfarin for whom genotype-guided dosing is cost-effective (36). Indeed, cost-
effective analyses have been conducted using pharmacogenetic information in warfarin 
dosing for patients with nonvalvular atrial fibrillation (37). Based on a Markov state 
transition decision model with effectiveness measured by quality-adjusted life-years 
(QALYs), it was shown that warfarin-related genotyping is unlikely to be cost-effective for 
typical patients, but may be cost-effective in those at high risk for hemorrhage who will be 
started on warfarin therapy. Recent work has demonstrated its cost-effectiveness in other 
conditions such as mechanical heart valve replacement (38).  
In 11 of the 18 trials, genotype-guided therapy arm was compared with a fixed dosing 
strategy in the standard care arm. In these studies, it is difficult to attribute the beneficial 
effects entirely to genotyping because patients in this group also benefited from the 
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algorithms or regression models using clinical information, which also contributed to the 
accuracy of warfarin dosing. Therefore, the benefits of genotype-guided therapy alone are 
better estimated by comparing to the remaining seven studies using clinical information 
guided approach in the standard care arm. There was no apparent improvement in TTR, 
excessive anticoagulation, risk of thromboembolism or mortality between the genotype-
guided and the clinical information-guided groups, although there may be a benefit in 
reducing bleeding events. From the previous meta-analyses (15-21), only three had 
performed subgroup analyses based on the dosing regimen in the control group (18, 20, 21). 
All of these three meta-analyses similarly demonstrated no significant improvement in either 
biochemical parameters of INR control or the clinical endpoints of bleeding and 
thromboembolism events in the genotype-guided warfarin dosing group when compared to 
the clinical information-guided group using an equation-based approach. 
 
Strengths and limitations 
There are many strengths of this study. It is the largest meta-analysis of randomized 
trials to date, including 5230 participants from 18 trials. No heterogeneity or a low level of 
heterogeneity was observed for our meta-analyses on excessive anticoagulation, bleeding, 
thromboembolism or mortality. Heterogeneity remained low even when different types of 
control groups (fixed dosing and clinical information-guided dosing) were analyzed together, 
indicating the appropriateness to do pool these studies.  
However, several limitations inherent in the present meta-analysis should be noted. 
Firstly, significant heterogeneity was observed for time-to-stable INR analysis. Similarly, the 
meta-analysis of TTR showed high level of heterogeneity, which was only partially 
accounted for when fixed dosing and clinical information-guided dosing were analyzed 
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separately. Some of the heterogeneity may be clinical as a result of different patient 
populations studied, such as different indications for anticoagulation. As described above, 
any small benefits in lowering the risk of bleeding may be magnified in orthopedic surgery 
because of the presence of open surgical wounds. Secondly, our meta-analysis only focused 
on one coumarin anticoagulant, warfarin, but not others. For example, acenocoumarol and 
phenprocoumon, which may be more commonly prescribed in some countries, were not 
included. Whether genotype-guided dosing similarly is better than conventional dosing 
strategies await further analyses. Moreover, the mean follow-up duration was 64 days. Whilst 
this is sufficient for evaluating time-to-first therapeutic INR and time-to-stable INR, it cannot 
provide the full picture in terms of clinical outcomes. Furthermore, there appears to be 
considerable heterogeneity among the genotype testing regimens. Finally, although 
differences in bleeding rates could be detected in our meta-analysis, our study may not be 
powered sufficiently to detect differences in thromboembolism or mortality. Future work can 
also analyze whether the effectiveness similar in the perioperative period as compared with 
other clinical indications. 
 
Conclusions 
Genotype-guided warfarin dosing offers better safety with less bleeding for patients 
requiring anticoagulation compared to conventional dosing strategies. No significant benefit 
on thromboembolism or mortality was evident. 
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Figure 1. Flowchart of the database search and study selection process. 
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Figure 2. Mean difference in time-to-first therapeutic INR based on control group dosing 
regimen (top left panel) or ethnicity (top right panel). Mean difference in time-to-first stable 
INR based on control group dosing regimen (bottom left panel) or ethnicity (bottom right 
panel).  
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Figure 3. Mean difference in TTR based on control group dosing regimen (top left panel) or 
ethnicity (top right panel). Risk ratios comparing the number of individuals with excessive 
anticoagulation, defined as INR ≥ 4 between genotype-guided warfarin dosing and 
conventional dosing groups based on control group dosing regimen (bottom left panel) or 
ethnicity (bottom right panel). 
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Figure 4. Risk ratios for comparing the number of individuals with bleeding symptoms 
between the genotype-guided warfarin dosing and conventional dosing groups based on 
control group dosing regimen (top left panel) or ethnicity (top right panel) with 
thromboembolism based on control group dosing regimen (bottom left panel) or ethnicity 
(bottom right panel). 
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Figure 5. Risk ratios for comparing the mortality between the genotype-guided warfarin 
dosing and conventional dosing groups based on control group dosing regimen (left panel) or 
ethnicity (right panel). 
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Table 1. Characteristics of the trials included in this meta-analysis. 
First author 
surname and 
year of 
publication 
Target 
INR 
Follow
-up 
(days) 
Ethnicity Indication for 
warfarin 
Genotype-
guided 
group 
genes 
tested 
Genotype-
guided 
group 
dosing 
algorithm 
Genotype
-guided 
group 
total no. 
Genotype
-guided 
group no. 
of males 
Genotype
-guided 
group 
age, SD  
(yrs) 
Control 
group dosing 
algorithm 
Control 
group 
total 
no. 
Control 
group 
no. of 
males 
Control 
group  
age, SD  
(yrs) 
Ref 
Hillman 
2005 
1.9-3.2 28 ± 0 Caucasian 
(100%) 
AF, DVT/PE, 
elective 
valvuloplasty or 
arthroplasty 
CYP2C9 Hillman 
equation 
18 8 68.8 ± 
11.3 
Fixed (5 mg 
for 7 days) 
20 9 70.5 ± 
13.3 
(4) 
Anderson 
2007 
2.0-3.0 46 ± 
32 
Caucasian 
(95%) 
AF, DVT/PE, 
orthopedic 
surgery, others 
CYP2C9, 
VKORC1 
Carlquist 
equation 
101 50 63.2 ± 
15.3 
Fixed (10 
mg, 10 mg, 5 
mg) 
99 56 58.9 ± 
16.0 
(5) 
Caraco 2008 2.0-3.0 31 ± 
22 
Not reported 
(Israeli 
patients) 
AF, DVT/PE CYP2C9 Algorithm 
designed 
by the 
authors 
95 46 57.6 ± 
19.6 
Fixed (5 mg 
for an 
average of 
6.5 days) 
96 42 59.7 ± 
18.5 
(6) 
Huang 2009 1.8-3.0 50 ± 0 Han Chinese 
(100%) 
AF, DVT, valve 
replacement 
CYP2C9, 
VKORC1 
Sheng-
WenHuan
g equation 
61 20 41.6 ± 
9.6 
Fixed (2.5 
mg; did not 
describe how 
many days) 
60 18 43.0 ± 
10.8 
(7) 
Borgman 
2012 
1.8-3.2 90 ± 0 Caucasian 
(100% in 
genotype 
group; 85% in 
conventional 
dosing)  
AF, DVT, stroke, 
others 
CYP2C9, 
VKORC1 
5 mg + 
PerMIT 
software 
13 7 59.0 ± 
12.3 
Fixed (5 mg 
for 7 days, 
but clinicians 
allowed to 
deviate) 
13 7 45.0 ± 
17.3 
(9) 
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Wang 2012 1.8-3.0 50 ± 0 Han Chinese 
(100%) 
Valve replacement 
for rheumatic 
heart disease 
CYP2C9, 
VKORC1 
Sheng-
WenHuan
g equation 
53 15 41.9 ± 
6.3 
Fixed (2.5 
mg for 3 
days) 
53 16 42.8 ± 
8.5 
(10) 
Pirmohamed 
2013 
2.0-3.0 90 ± 0 Caucasian 
(98.5%), 
African 
(1.1%), Asian 
(0.4%) 
AF, DVT/PE CYP2C9, 
VKORC1 
Modified 
IWPC 
algorithm 
227 145 67.8 ± 
14.5 
Fixed (10/5 
mg, 5 mg, 5 
mg) 
228 132 66.9 ± 
12.9 
(14) 
Pengo 2015 2.0-3.0 30 ± 0 Italian 
Caucasian 
(100%) 
AF CYP2C9, 
VKORC1, 
CYP4F2 
Hamberg 
equation 
88 58 71.0 ± 
11.3 
Fixed (5 mg 
for 4 days) 
92 60 75.0 ± 
10.0 
(22) 
Supe 2015 2.0-3.0 21 ± 0 Croatian 
Caucasian 
(100%) 
Acute stroke CYP2C9, 
VKORC1 
IWPC 
algorithm 
106 46 67.6 ± 
13.5 
Fixed (6 mg 
for days 2 to 
5) 
104 42 69.1 ± 
12.2 
(23) 
Wen 2017 2.0-3.0 90 ± 0 Han Chinese 
(100%)  
AF, DVT, PE, 
stroke, others 
CYP2C9, 
VKORC1 
Wen et al. 
algorithm 
107 59 67.0 ± 
15.5 
Fixed (5 mg 
for 3 days) 
104 63 66.0 ± 
14.0 
(27) 
Jin 2017 2.0-3.0 84 ± 0 Han Chinese 
(100%) 
PE CYP2C9, 
VKORC1 
IWPC 
algorithm 
115 57 69.0 ± 
12.0 
Fixed (3 mg) 123 63 68.0 ± 
12.0 
(26) 
Burmester 
2011 
2.0-3.5 60 ± 0 Caucasian 
including 
Hispanics 
(100%) 
AF, DVT/PE, 
valve surgery 
CYP2C9, 
VKORC1, 
CYP4F2 
Burmester 
equation 
115 66 67.4 ± 
12.3 
CI 
(Burmester 
equation, 
regression 
model based 
on age, 
gender, BSA, 
heart valve 
status) 
115 70 69.2 ± 
12.7 
(8) 
 
 
This article is protected by copyright. All rights reserved. 
Radhakrishn
an 2012 
N/A 90 ± 0 Not mentioned 
(U.S. study 
based in  
Pittsburgh) 
Any indication 
(not elaborated 
further) 
CYP2C9, 
VKORC1 
N/A 28 - - CI (N/A) 28 - - (29) 
Li 2013 2.0-3.0 50 ± 0 Han Chinese 
(100%) 
PE CYP2C9, 
VKORC1 
Li et al. 
algorithm 
97 38 61.6 ± 
13.6 
CI 
(empirically 
by clinician 
for first 3 
doses) 
95 38 60.1 ± 
14.2 
(13) 
Jonas 2013 2.0-3.5 90 ± 0 Caucasian 
(72.5%), 
African-
American 
(27.5%) 
AF, DVT, PE, 
heart valve, others 
CYP2C9, 
VKORC1 
Gage 
equation 
55 24 59.0 ± 
19.3 
CI (Gage 
equation) 
54 27 55.3 ± 
19.1 
(11) 
Kimmel 
2013 
2.0-3.0 30 ± 0 Caucasian 
(66.5%), 
African 
(27.1%), 
Hispanic 
(6.4%) 
AF, DVT/PE, 
multiple 
indications, other 
indications, no 
indication given 
CYP2C9, 
VKORC1 
Gage 
equation 
514 272 59.0 ± 
16.3 
CI (Gage 
equation, 
based on  
age, BSA, 
African 
American 
race, 
amiodarone 
use, target 
INR, 
smoking 
status, and 
warfarin 
indication) 
501 246 57.0 ± 
16.3 
(12) 
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Abbreviations: AF: atrial fibrillation; BSA: body surface area; DVT: deep vein thrombosis; PE: pulmonary embolism; CI: clinical information  
 
 
 
Duan 2016 N/A 28 ± 0 Han Chinese 
(100%) 
PE with or 
without DVT 
CYP2C9, 
VKORC1 
N/A 25 10 54.5 ± 
14.9 
CI 
(traditional 
model) 
30 13 54.5 ± 
14.9 
(24) 
Gage 2017 1.5-2.1 
(50%), 
2.0-3.0 
(50%) 
90 ± 0 Caucasian 
(91.0%), 
African 
(6.4%),  Asian 
or Indian 
subcontinent 
(1.8%), 
American 
Indian or 
Alaskan 
Native (0.1%), 
others 
Arthroplasty CYP2C9, 
VKORC1, 
CYP4F2 
IWPC 
algorithm 
808 286 72.2 ± 
5.3 
CI (Gage 
equation, 
based on  
age, BSA, 
African 
American 
race, 
amiodarone 
use, target 
INR, 
smoking 
status, and 
warfarin 
indication) 
789 293 72.0 ± 
5.5 
(25) 
